Although the systemic chemotherapy combined with local-control therapy is still the general discipline for advanced NSCLC patients with BM, compelling data has shown the superior efficacy of TKIs than chemotherapy as the first-line therapy in EGFR mutant patients 23-25. This evidence concerns the gene EGFR and non-small cell lung carcinoma.